JPWO2010110366A1 - Pharmaceutical composition container - Google Patents

Abstract

It can be swallowed easily, scattering of the pharmaceutical composition in the mouth can be suppressed, and the pharmaceutical composition can be easily filled. The pharmaceutical composition container 10 includes a plurality of spaces 30 and 32. Between two adjacent spaces 70 and 72 are closed. The space 70 between two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container 10. A swallowing aid substance 40 is housed in the swallowing aid substance storage chamber 30. A stored item 42 is stored in the stored item storage chamber 32. The inclusion 42 contains a pharmaceutical composition 80. An opening formation scheduled portion 60 is provided on the sheet 20. The opening formation scheduled portion 60 is a portion where the opening is scheduled to be formed. The opening allows communication between the outside of the pharmaceutical composition container 10 and the spaces 30 and 32.

Description

  The present invention relates to a pharmaceutical composition container, and more particularly, to a pharmaceutical composition container capable of reducing the residual amount of the pharmaceutical composition.

  When taking a pharmaceutical composition such as a powder or granule, it is generally swallowed using water. However, since this pharmaceutical composition is swallowed by swallowing water after receiving it on the tongue once, there is a problem that a part of the composition remains in the mouth forever or is stimulated by medicinal ingredients, Because it is taken with high-quality water, there are problems such as being unable to take it lying down.

  Patent Document 1 discloses a multi-chamber container. This multi-chamber container partitions a plurality of spaces so as to communicate with each other. These spaces are closed in a state where they can communicate with each other by a force applied from the outside. In any of these spaces, the granular agent is accommodated in a sealed state. The other space contains a dense fluid substance in a sealed state. Each space is communicated with each other, and after the granular material and the concentrated fluid substance are collected and mixed, the mixture can be taken out from a take-out port provided in any one of the spaces.

  According to the container disclosed in Patent Document 1, it is possible to take the granular agent by an extremely simple operation. Moreover, according to the multi-chamber container disclosed in Patent Document 1, the patient's resistance to taking can be greatly reduced.

Japanese Patent Laid-Open No. 10-234820

  However, in the invention started in Patent Document 1, when the pharmaceutical composition is a powder, powder or granule, there is a problem that there is a high possibility that they remain in the multi-chamber container.

  The technical problem of the present invention was made to solve the above problems, and an object of the present invention is to provide a pharmaceutical composition container that can reduce the residual amount of the pharmaceutical composition. .

  The pharmaceutical composition container of the present invention will be described with reference to the drawings. Note that the use of the reference numerals in the figure in this column is intended to assist understanding of the contents of the invention, and is not intended to limit the contents to the illustrated range.

  In order to achieve the above object, according to one aspect of the present invention, the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 has a plurality of spaces 30, 32, 34, 36, 38, 100, 102, 104, 106, 110, 112, 114, 116, 150 are provided. Between two adjacent spaces, 70, 72, and 76 are closed. The space 70, 72, 76 between two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18. The swallowing assisting substance 40 is accommodated in the swallowing assisting substance accommodating chambers 30, 100, 102, 104, 106 which are at least one of the spaces. The inclusions 42 and 120 are accommodated in the inclusion storage chambers 32, 110, 112, and 114, which are at least one of the spaces. The inclusions 42 and 120 contain a pharmaceutical composition 80. At least the surface of the inclusions 42 and 120 is dissolved in the component of the swallowing auxiliary substance 40. The pharmaceutical composition containers 10, 11, 12, 14, 15, 16, 18 are provided with an opening formation scheduled portion 60. The opening formation scheduled portion 60 is a portion where the opening is scheduled to be formed. The openings are located outside the pharmaceutical composition containers 10, 11, 12, 14, 15, 16, 18 and spaces 30, 32, 34, 36, 38, 100, 102, 104, 106, 110, 112, 114, 116, Communicate with 150.

  Between two adjacent spaces 70, 71, 72, 76 are closed. The space 70, 71, 72, 76 between two adjacent spaces opens when a force applied from the outside of the pharmaceutical composition container 10, 11, 12, 14, 15, 16, 18 is applied. By opening 70, 71, 72, 76 between two adjacent spaces, the swallowing assisting substance 40 is moved from the swallowing assisting substance accommodating chambers 30, 100, 102, 104, 106 to the inclusion accommodating chambers 32, 110, 112, 114. It becomes possible to guide to. Thereby, after the opening is formed in the opening formation scheduled portion 60, when the opening is placed on the mouth of a person who has difficulty in swallowing and the swallowing auxiliary substance 40 and the inclusions 42 and 120 are pushed out from the opening, the swallowing auxiliary substance 40 The inclusions 42 and 120 are placed in the mouth of a person who is difficult to swallow in the state of being wrapped in the container. The inclusions 42, 120 are swallowed. Since the pharmaceutical composition 80 is contained in the storages 42 and 120, when the storages 42 and 120 are pushed out, the pharmaceutical composition 80 in the storages 42 and 120 is also pushed out at the same time. As a result, the residual amount of the pharmaceutical composition 80 in the storage chambers 32, 110, 112, and 114 is lower than when the pharmaceutical composition 80 is not contained in the storages 42 and 120. When at least the surface of the inclusions 42 and 120 is dissolved with respect to the component of the swallowing auxiliary substance 40, the swallowing auxiliary substance 40 is guided to the inclusion containing chambers 32, 110, 112, and 114 and then the inclusions 42 and 120. The surface will melt. Since the surface is melted after being wrapped in the swallowing auxiliary substance 40, even if it is difficult for swallowing, the stored items 42 and 120 can be swallowed easily. By swallowing the inclusions 42 and 120, the pharmaceutical composition 80 is also swallowed.

  Moreover, it is desirable that the above-described swallowing assisting substance 40 contains moisture. In this case, the material of the inclusions 42 and 120 is a water-soluble substance. Thereby, since the surface of the inclusions 42 and 120 is not sufficiently dissolved, the possibility of difficulty in swallowing is reduced.

  Alternatively, it is desirable that the above-described swallowing aid substance 40 is a jelly containing moisture. In this case, it is desirable that the water-soluble substance is starch.

  In addition, it is desirable that the vacant chamber 116 that is at least one of the above-described spaces is disposed between the swallowing auxiliary substance storage chamber 102 and the stored material storage chamber 114. When the vacant space 116 is provided, the swallowing aid substance 40 is contained in the inclusion 42 when the two adjacent spaces 102 and 114 communicate with each other against the intention of the user or the handler of the pharmaceutical composition container 15. The possibility of touching is reduced. If the possibility becomes low, the possibility that the encapsulated material 42 will dissolve before taking the pharmaceutical composition 80 also becomes low. As a result, the pharmaceutical composition container 15 is easy to store and easy to handle.

  Moreover, it is desirable that the above-mentioned inclusion 42 is sealed. In addition, “sealing” in the present specification means being closed so that there is no gap.

  According to another aspect of the present invention, the pharmaceutical composition containers 210, 260, 400, 500 have at least three spaces 230, 232, 234, 236, 280, 282, 284, 286, 422, 424, 426, 520, 522, 524, and 526 are provided. Between two adjacent spaces, 240, 242, 244, 300, 302, 304, 440, 442, 444, 540, 542, and 544 are closed. Between the two adjacent spaces 240, 242, 244, 300, 302, 304, 440, 442, 444, 540, 542, 544, a force is applied from the outside of the pharmaceutical composition container 210, 260, 400, 500. And open. The swallowing assisting substance 40 is accommodated in the swallowing assisting substance accommodating chambers 230, 280, 520 which are at least one of the spaces. The storage 212 is stored in the storage chambers 232, 234, 282, 284, 422, 424, 522, and 524, which are at least one of the spaces. The inclusion 212 contains a pharmaceutical composition 80. At least the surface of the inclusion 212 is dissolved in the component of the swallowing auxiliary substance 40. An opening is provided in the opening chambers 236, 286, 426, and 526 which are at least one of the spaces. The opening communicates the outside of the pharmaceutical composition container 210, 260, 400, 500 with the space 230, 232, 234, 236, 280, 282, 284, 286, 422, 424, 426, 520, 522, 524, 526. .

  According to the present invention, the residual amount of the pharmaceutical composition can be reduced.

It is a partially broken view of the pharmaceutical composition container according to the first embodiment of the present invention. It is a figure which shows the use condition of the pharmaceutical composition container concerning 1st Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning the 1st modification of this invention. It is a partially broken figure of the pharmaceutical composition container concerning the 2nd modification of this invention. It is a partially broken figure of the pharmaceutical composition container concerning the 3rd modification of this invention. It is a partially broken figure of the pharmaceutical composition container concerning the 4th modification of the present invention. It is a partially broken figure of the pharmaceutical composition container concerning the 5th modification of this invention. It is a partially broken figure of the pharmaceutical composition container concerning the 6th modification of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 2nd Embodiment of this invention. It is an external view of the pharmaceutical composition container concerning 2nd Embodiment of this invention. It is a figure which shows the condition where the cover insertion part is inserted in the cover concerning 2nd Embodiment of this invention, and the root has come out of the cover. It is a rear view of the situation where the cover insertion part is inserted in the cover concerning a 2nd embodiment of the present invention. It is a partially broken figure of the pharmaceutical composition container concerning 3rd Embodiment of this invention. It is a figure which shows the condition which is bending the pharmaceutical composition container concerning 3rd Embodiment of this invention. It is a figure which shows the condition after one end is inserted in the cover in the pharmaceutical composition container concerning 3rd Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 4th Embodiment of this invention. It is a partially broken figure which shows the one end part in manufacture of the pharmaceutical composition container concerning 4th Embodiment of this invention. It is a perspective view which shows the one end part in manufacture of the pharmaceutical composition container concerning 4th Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 5th Embodiment of this invention. It is a figure which shows the condition which wound the pharmaceutical composition container concerning 5th Embodiment of this invention.

  Hereinafter, embodiments of the present invention will be described with reference to the drawings. In the following description, the same parts are denoted by the same reference numerals. Their names and functions are also the same. Therefore, detailed description thereof will not be repeated.

<First embodiment>
FIG. 1 is a partially cutaway view of a pharmaceutical composition container 10 according to the present embodiment. FIG. 2 is a diagram illustrating a usage state of the pharmaceutical composition container 10 according to the present embodiment.

  The pharmaceutical composition container 10 according to the present embodiment is affixed around the sheets 20 and 20 made of two synthetic resins that are superposed on each other (preferably a soft material that can be folded, such as low-density polyethylene). It is formed by combining. In the pharmaceutical composition container 10, a swallowing auxiliary substance storage chamber 30, a stored material storage chamber 32, and an outlet chamber 34 are formed. The swallowing auxiliary substance storage chamber 30, the inclusion storage chamber 32, and the outlet chamber 34 are formed so as to maintain airtightness with respect to the external space. The swallowing auxiliary substance storage chamber 30, the stored item storage chamber 32, and the outlet chamber 34 are arranged in a line.

  A swallowing auxiliary substance 40 is accommodated in the swallowing auxiliary substance storage chamber 30. The swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing water. In the present embodiment, the moisture content of the jelly is set so as to ensure at least 2 minutes from when the swallowing auxiliary substance 40 covers the surface of the inclusion 42 described later until the inclusion 42 is completely dissolved. Until the 2nd weak seal part 72 mentioned later peels, the exit chamber 34 in this embodiment is an empty room.

  A storage 42 made of oblate is stored in the storage chamber 32. A granulated drug or other pharmaceutical composition 80 is accommodated in the inclusion 42. The inclusion 42 according to the present embodiment is obtained by putting the pharmaceutical composition 80 in a commercially available wafer and twisting a portion corresponding to the entrance of the pharmaceutical composition 80. Thereby, the stored item 42 is sealed. However, in this embodiment, a starch wafer having a thickness of 10 μm is used. This is used in order to secure at least 2 minutes from when the swallowing auxiliary substance 40 covers the surface of the storage 42 until the storage 42 is completely dissolved. Of course, the thickness of the wafer should be appropriately selected according to the material.

  Note that a gas (for example, nitrogen gas) that does not affect the pharmaceutical composition 80 and the swallowing auxiliary substance 40 is enclosed in the storage container 32 and the swallowing auxiliary substance holding room 30 as necessary.

  The swallowing auxiliary substance storage chamber 30 and the stored item storage chamber 32 are partitioned by a first weak seal portion 70. The inclusion storage chamber 32 and the outlet chamber 34 are partitioned by a second weak seal portion 72. The first weak seal portion 70 and the second weak seal portion 72 are portions between two adjacent spaces among the bonded portions of the two sheets 20 and 20. The strength of the first weak seal portion 70 and the second weak seal portion 72 is such that the outer peripheral strong seal portion 74 (the first weak seal portion 70 and the second weak seal among the portions where the two sheets 20 and 20 are bonded together). It is lower than the strength of the portion other than the seal portion 72). This can be achieved by using different materials for the adhesive when the two sheets 20 and 20 are bonded together. As a result, when the first weak seal portion 70 and the second weak seal portion 72 are pushed from the outside of the pharmaceutical composition container 10 when the swallowing auxiliary substance storage chamber 30 or the inclusion storage chamber 32 is pushed out of the pharmaceutical composition container 10, the swallowing auxiliary substance storage chamber 30. Or it peels easily with the force which the swallowing auxiliary | assistance substance 40 gives to the storage container 32. FIG. In other words, the swallowing auxiliary substance storage chamber 30 and the stored material storage chamber 32 are closed in a state where they can communicate with each other by a force applied from the outside of the pharmaceutical composition container 10.

  On both sides of the outlet chamber 34, a pair of cut portions 50 each having a V-shaped cut are formed. The opening formation scheduled portion 60 sandwiched between the cut portions 50 is a portion where the opening is scheduled to be formed. This opening allows the outside and the inside of the outlet chamber 34 to communicate.

  The procedure for taking out the pharmaceutical composition 80 from the pharmaceutical composition container 10 and taking it will be described with reference to FIG.

  First, a caregiver or the like pushes the swallowing auxiliary substance storage chamber 30 from the outside of the pharmaceutical composition container 10 and peels the first weak seal portion 70 by pressure from the inside of the swallowing auxiliary substance storage chamber 30. When the first weak seal portion 70 is peeled off, the swallowing auxiliary substance 40 is pushed out into the storage container chamber 32. The pushed swallowing auxiliary substance 40 spreads in the storage container chamber 32 and fills the periphery of the storage object 42. From this time, the surface of the inclusion 42 starts to melt by the swallowing aid 40.

  After the swallowing auxiliary substance 40 is pushed out into the storage container chamber 32, a caregiver or a patient 90 squeezes the pharmaceutical composition container 10 in a direction from the swallowing auxiliary substance storage chamber 30 toward the storage container chamber 32. Thereby, as a result of the pressure being applied to the swallowing auxiliary substance 40, the second weak seal portion 72 is peeled off. When the second weak seal portion 72 is peeled off, the swallowing auxiliary substance 40 and the inclusion 42 are pushed out to the outlet chamber 34. When the swallowing auxiliary substance 40 and the inclusion 42 are pushed out to the outlet chamber 34, a caregiver, a patient 90, or the like applies a shearing force to the incision portion 50 to provide an opening in the outlet chamber 34. When the opening is provided, a caregiver, a patient 90, or the like places the opening on the patient's mouth and squeezes the pharmaceutical composition container 10 from the swallowing auxiliary substance storage chamber 30 toward the storage container 32. As a result, the inclusion 42 covered with the swallowing auxiliary substance 40 enters the mouth of the patient 90. FIG. 2 shows a situation where the patient 90 is squeezing the pharmaceutical composition container 10. At this time, since the surface of the inclusion 42 is dissolved in the component of the swallowing auxiliary substance 40, the surface of the inclusion 42 is easily slipped. Since the surface of the inclusion 42 is easy to slide, the inclusion 42 is swallowed smoothly.

  As described above, the pharmaceutical composition container 10 according to the present embodiment has the following effects. The first effect is that the granular drug or other pharmaceutical composition 80 can be swallowed easily. The second effect is that the taste such as the bitterness of the drug is suppressed. The third effect is an effect that the pharmaceutical composition 80 can be prevented from being scattered in the mouth. The fourth effect is that there is no need to worry about the stability of the drug. The fifth effect is an effect that various kinds of solids can be taken by a person who has difficulty in swallowing. The sixth effect is that the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 10 can be reduced (in the case of the present embodiment, the residual amount can be made an amount close to zero). .

  The first effect will be described in detail. The inclusion 42 enters the mouth of the patient 90 in a state of being wrapped in the swallowing auxiliary substance 40. At this time, the surface of the inclusion 42 is melted. Since the surface is melted while being wrapped in the swallowing assisting material 40, even the patient 90 who is difficult to swallow can easily swallow the stored matter 42. Since the encapsulated product 42 contains the pharmaceutical composition 80, the medicinal composition 80 is also swallowed by swallowing the encapsulated product 42. Thereby, the pharmaceutical composition 80 can be swallowed easily.

  The second effect will be described in detail. As described above, the inclusion 42 enters the mouth of the patient 90 in a state of being wrapped in the swallowing auxiliary substance 40. Thereby, the pharmaceutical composition 80 which is the content of the stored product 42 is double-wrapped by the swallowing auxiliary substance 40 and the stored product 42. Since the pharmaceutical composition 80 is wrapped in a double layer, even if the pharmaceutical composition 80 is a drug, the possibility that the tongue of the patient 90 senses its taste such as bitterness is low. As a result, the taste such as the bitterness of the drug is suppressed.

  The third effect will be described in detail. As described above, the pharmaceutical composition 80 is double-wrapped by the swallowing auxiliary substance 40 and the inclusion 42. Thereby, the possibility that the pharmaceutical composition 80 is scattered in the mouth of the patient 90 is reduced. As a result, scattering of the pharmaceutical composition 80 in the mouth can be suppressed.

  The fourth effect will be described in detail. The drug is a chemical substance. When chemical substances come into contact, chemical reactions often occur. Due to the chemical reaction, the drug loses its medicinal properties. For this reason, in many cases, a plurality of drugs cannot be stored in a mixed state. When storing them in a mixed state, it is necessary to check in advance whether their medicinal properties are lost. The pharmaceutical composition container 10 according to the present embodiment is provided with a plurality of spaces. Storing one type of drug in each space and storing a plurality of drugs separately are substantially the same. This is the reason why it is not necessary to worry about the stability of the drug if the pharmaceutical composition container 10 according to this embodiment is used. Since there is no need to worry about the stability of the drugs, there is no need to examine in advance whether the efficacy of a plurality of drugs has been lost.

  The fifth effect will be described. After the swallowing assisting substance 40 is guided to the storage container chamber 32, the swallowing assisting substance 40 and the storing object 42 are swallowed, so that the activity of the pharmaceutical composition 80 itself does not have a great influence on the difficulty of swallowing. Thereby, various kinds of solids can be taken for those who have difficulty in swallowing.

  The sixth effect will be described. When the swallowing auxiliary substance 40 and the stored product 42 are pushed out from the opening formed in the pharmaceutical composition container 10, the pharmaceutical composition 80 in the stored product 42 is also pushed out at the same time. Thereby, the residual amount of the pharmaceutical composition 80 in the stored material storage chamber 32 is significantly reduced as compared with the case where the stored pharmaceutical product 80 is not contained in the stored product 42. In addition, the container 42 according to the present embodiment is sealed. Since it is sealed, the possibility of the pharmaceutical composition 80 leaking out of the inclusion 42 is very low. Since the possibility is extremely low, the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 10 can be reduced (actually, the residual amount is made close to zero).

  The pharmaceutical composition container 10 described in the present embodiment is illustrated to embody the technical idea of the present invention. This does not limit the material of the sheet 20 to the above-described embodiment. This does not limit the shape of the sheet 20, the shape of each space, the shape of the opening, their dimensions, their structure, their arrangement, and the like to the above-described embodiment. The pharmaceutical composition container 10 described in the present embodiment can be variously modified within the scope of the technical idea of the present invention.

  For example, FIG. 3 is a partially cutaway view of the pharmaceutical composition container 12 according to the first modification. In the pharmaceutical composition container 12, the first tapered portion 130 of the swallowing auxiliary substance storage chamber 100 that faces the storage container 110 is gradually narrowed toward the storage container 110. The 2nd taper part 140 which opposes the swallowing auxiliary substance storage chamber 100 among the inclusion storage rooms 110 is gradually narrowed toward the swallowing auxiliary substance storage chamber 100. Thereby, when the 1st weak seal | sticker part 70 is peeled and the swallowing assistance substance 40 is pushed out to the storage container chamber 110, possibility that the whole quantity of the swallowing assistance substance 40 will be pushed out becomes high.

  Moreover, it replaces with the storage 42 as shown in FIG. 1, and the bag-like storage 120 as shown in FIG. 3 may be accommodated. Of course, the stored item 120 may be accommodated in the pharmaceutical composition container 10 shown in FIG. Furthermore, the shape of the inclusion is not limited to that shown in FIGS. For example, instead of the inclusions 42 and 120, a known capsule may be accommodated as the inclusion. As described above, the swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing moisture. For this reason, when a well-known capsule is accommodated as a storage thing, the surface of the capsule melt | dissolves with respect to the water | moisture content which is a component of the swallowing assistance substance 40. FIG. Thereafter, the capsule dissolves in the digestive juice inside the stomach and intestines.

  Moreover, the space with which one pharmaceutical composition container is provided may be only two, and may be three or more. FIG. 4 is a partially cutaway view of the pharmaceutical composition container 14 according to the second modification. In the pharmaceutical composition container 14, a swallowing auxiliary substance storage chamber 102, a first storage container storage chamber 112, a second storage container storage chamber 114, and an outlet chamber 150 are formed. The swallowing auxiliary substance storage chamber 102, the first storage container storage chamber 112, the second storage container storage chamber 114, and the outlet chamber 150 are arranged in a line. Note that the end of the first storage container chamber 112 on the second storage container chamber 114 side becomes narrower as it approaches the second storage container chamber 114 and is stored in the first storage container chamber 112. Since the object 42 is accommodated, when the inclusion 42 is pushed out by the swallowing auxiliary substance 40, it can be smoothly performed. Since the end of the second storage chamber 114 on the outlet chamber 150 side becomes narrower as it approaches the outlet chamber 150, and the storage 42 is stored in the second storage chamber 114, this end The inclusion 42 is also pushed out with the same smoothness. Incidentally, instead of storing the storage 42 in the first storage chamber 112 and the second storage chamber 114, a bag-shaped storage 120 as shown in FIG. 3 may be stored.

  In addition, a vacant space may be provided between the swallowing auxiliary substance storage chamber and the stored item storage chamber. The vacant room is a space in which nothing is accommodated or a gas that does not affect the pharmaceutical composition 80 or the swallowing auxiliary substance 40 is accommodated. FIG. 5 is a partially cutaway view of a pharmaceutical composition container 15 according to a third modification. A vacant chamber 116 is provided instead of the first storage container chamber 112 shown in FIG. If the vacant chamber 116 is provided, the possibility of mixing the swallowing aid substance 40 and the pharmaceutical composition 80 can be reduced to some extent even if the sealing performance between the spaces is impaired due to an accident. If the pharmaceutical composition container 15 can be bent at the portion of the empty space 116, the possibility of mixing the swallowing aid substance 40 and the pharmaceutical composition 80 can be further reduced by bending that portion.

  Further, the pharmaceutical composition container is not limited to a laminate of two sheets. FIG. 6 is a partially cutaway view of the pharmaceutical composition container 16 according to the fourth modification. FIG. 7 is a partially cutaway view of a pharmaceutical composition container 18 according to a fifth modification. These are formed by folding one sheet in half. When the pharmaceutical composition containers 16 and 18 are formed by folding one sheet in half, the swallowing assistance substance containing chamber 104, compared to the pharmaceutical composition container formed by bonding two sheets with the same outer diameter. The volume of 106 can be increased. When the volume of the swallowing auxiliary substance storage chambers 104 and 106 increases, the amount of swallowing auxiliary substance 40 charged can be increased. In addition, the pharmaceutical composition container may be obtained by pasting together portions of one tube.

  Moreover, in the pharmaceutical composition container mentioned above, although the cutting part 50 was comprised by the V-shaped cut end, shapes other than V shape may be sufficient as the cutting part of this invention.

  In the above embodiment, the case where the pharmaceutical composition is a powder or granule and the swallowing auxiliary substance is jelly has been described, but the pharmaceutical composition and the swallowing auxiliary substance applied to the present invention are not limited thereto. Needless to say. For example, the pharmaceutical composition may be a tablet, capsule or simple mass in addition to powder or granule. The swallowing aid may be honey, custard cream, peanut spread, cheese spread, etc. in addition to an aqueous solution. Furthermore, the thing shape | molded as a pharmaceutical composition is not limited to the thing normally handled as a pharmaceutical. For example, the product molded as a pharmaceutical composition may be a food that has been recognized to improve health.

  As materials for the inclusions, various materials that have been conventionally used as materials for edible films can be used in addition to the above-mentioned 10 μm-thick starch oblate. These materials include polysaccharides (eg, pullulan, arabinoxylan, guar gum degradation products, sodium alginate, carrageenan, agar, pectin, cellulose, etc.) and peptide substances (eg, gelatin, silk protein degradation products, casein) Decomposition products). These materials can be used alone or in combination of two or more.

  In the above embodiment, the outlet chambers 34 and 150 are described. However, the outlet chamber 34 is not provided, and the notch 50 is provided in the storage chamber 32 or the like. An opening may be provided by applying a shearing force to the portion 50, and the opening may be applied to the patient's mouth.

  Moreover, the structure of 70,71,72 between two adjacent spaces may differ from what was mentioned above. For example, a thin film may be formed between two adjacent spaces 70, 71, 72. Such a film can be formed by sandwiching a member to be a film between two sheets 20 and 20 and bonding them together. However, the structure of 70, 71, 72 between two adjacent spaces must be a structure that is closed in a state where they can communicate with each other by a force applied from the outside of the pharmaceutical composition container 10. This “force applied from the outside of the pharmaceutical composition container 10” may be a force directly applied to 70, 71, 72 between two adjacent spaces, or a force indirectly applied to one of them. There may be.

  Moreover, the swallowing auxiliary substance 40 may not be directly filled in the space provided in the pharmaceutical composition container. FIG. 8 is a partially cutaway view of the pharmaceutical composition container 11 according to the sixth modification. In the pharmaceutical composition container 11 according to the present embodiment, a first bag storage chamber 36, a second bag storage chamber 38, a stored item storage chamber 32, and an outlet chamber 34 are formed. Similar to the container storage chamber 32 and the outlet chamber 34, the first bag storage chamber 36 and the second bag storage chamber 38 are also formed so as to be airtight with respect to the external space.

  The first bag storage chamber 36 and the second bag storage chamber 38 store the auxiliary substance storage bag 22 and fix it. It is the outer peripheral strong seal portion 74 and the third weak seal portion 76 that directly fix the auxiliary substance containing bag 22. The strength of the third weak seal portion 76 against peeling is substantially the same as that of the outer peripheral strong seal portion 74.

  The auxiliary substance storage bag 22 stores the swallowing auxiliary substance 40. The strength of one end of the auxiliary substance storage bag 22 facing the first weak seal portion 70 is a strength that is broken by a force applied from the outside of the pharmaceutical composition container 11. The swallowing auxiliary substance 40 is sterilized together with the auxiliary substance containing bag 22, and is then sandwiched between the sheets 20 and 20 and adhered thereto. Thereafter, the outer peripheral strong seal portion 74 and the like are formed. Thereby, when force is applied from the outside of the pharmaceutical composition container 11, one end of the auxiliary substance storage bag 22 is peeled off. When it is peeled off, the swallowing auxiliary substance 40 leaks into the first bag storage chamber 36. At this time, when a force is further applied from the outside of the pharmaceutical composition container 11, the first weak seal portion 70 is peeled by the force received from the swallowing auxiliary substance 40. When the first weak seal portion 70 is peeled off, the inclusion 42 is wrapped in the swallowing aid substance 40.

<Second Embodiment>
Hereinafter, a second embodiment of the present invention will be described. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

<Description of structure>
FIG. 9 is a partially cutaway view of the pharmaceutical composition container 260 according to the present embodiment. The pharmaceutical composition container 260 according to the present embodiment is a single synthetic resin (low-density polyethylene, PET (polyethylene terephthalate), a soft resin that can be bent such as a composite resin thereof, and capable of heat sealing). It is formed by folding the manufactured sheet in half, pasting the ends of the half-folded sheet together, cutting out the pasted portion, and adjusting the outer shape.

  A portion where the ends of the sheet are bonded together is an outer peripheral strong seal portion 270. A plurality of spaces are provided inside the pharmaceutical composition container 260. Between these spaces, the first weak seal portion 300, the second weak seal portion 302, and the third weak seal portion 304 are closed. The first weak seal portion 300 includes a first weak seal band 310, an intermediate chamber 312, and a second weak seal band 314.

  One of the spaces inside the pharmaceutical composition container 260 is a swallowing auxiliary substance storage chamber 280. In the swallowing auxiliary substance storage chamber 280, the swallowing auxiliary substance 40 is stored. When a force is applied to the swallowing aid substance 40 from the outside of the pharmaceutical composition container 260, the first weak seal band 310 of the first weak seal portion 300 is easily opened by the pressure received from the swallowing aid substance 40. When the first weak seal band 310 is opened, the swallowing auxiliary substance 40 is pushed into the intermediate chamber 312. Thereafter, similarly, the second weak seal band 314, the second weak seal portion 302, and the third weak seal portion 304 are sequentially opened. This can be realized because the strength of the first weak seal portion 300, the second weak seal portion 302, and the third weak seal portion 304 is lower than that of the outer peripheral strong seal portion 270. The reason for this is the same as in the first embodiment, so the details will not be repeated here.

  One type of space inside the pharmaceutical composition container 260 includes a first storage container chamber 282 and a second storage container chamber 284. Each of these contains a container 212. The type of the pharmaceutical composition stored in the storage 212 stored in the first storage container 282 is different from that stored in the storage 212 stored in the second storage container 284.

  There is also an open chamber 286 in one of the spaces inside the pharmaceutical composition container 260. The opening chamber 286 is provided at one end of the pharmaceutical composition container 260 and serves as a chute for taking the stored product 212 (that is, a device for sliding the stored product 212 into the patient's mouth).

  Of the both ends of the pharmaceutical composition container 260, one end on the side opposite to the side where the opening chamber 286 is provided is a cover 288. The boundary between the swallowing auxiliary substance storage chamber 280 and the cover 288 is a bottom strong seal portion 272. Since the strength of the bottom strong seal portion 272 is the same as that of the outer peripheral strong seal portion 270, even if a force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 260, it does not peel off. In the description of the pharmaceutical composition container 260 according to the present embodiment, a portion closer to the second storage container 284 than the cover 288 is referred to as a “container body”.

  FIG. 10 is an external view of a portion corresponding to the back surface of the pharmaceutical composition container 260 according to this embodiment when viewed from the surface shown in FIG. 9. As is clear from FIG. 10, a label 262 is affixed to the pharmaceutical composition container 260 according to this embodiment.

<Features unique to this embodiment>
A characteristic of the pharmaceutical composition container 260 according to this embodiment when compared with the pharmaceutical composition container according to another embodiment is that a cover 288 is provided at one end and the other end is inserted into the cover 288. A cover insertion portion 320 is provided, and the width of the pharmaceutical composition container 260 is wide at the base 330 of the portion to be inserted into the cover 238, and a portion of the bottom strong seal portion 272 and the second weak seal portion 302 is provided. The third weak seal portion 304 is bent and the tip of the cover insertion portion 320 is inserted into the cover 238, and the root 330 protrudes from the cover 238. FIG. 11 shows a situation where the cover insertion portion 320 is inserted into the cover 238 and the root 330 is out of the cover 238. As can be seen from FIG. 11, the base 330 is recessed, and the cover insertion portion 320 can be easily pulled out by inserting a finger there. Note that FIG. 12 is a diagram of a portion corresponding to the back surface when viewed from the surface illustrated in FIG. 11 in the situation illustrated in FIG. 11. The label 262 occupies most of the back surface of the pharmaceutical composition container 260.

<Usage>
When using the pharmaceutical composition container 260 according to this embodiment, a finger is put on the base 330 described above, and the cover insertion portion 320 described above is pulled out from the cover 238 as it is. When the cover insertion portion 320 is withdrawn, the cover insertion portion 320 is placed in the patient's mouth. Subsequent usage is the same as in other embodiments and modifications thereof.

<Description of effects>
Since the pharmaceutical composition container 260 according to the present embodiment can put a finger on the base 330 of the cover insertion portion 320, the cover insertion portion 320 can be easily pulled out.

  Moreover, the pharmaceutical composition container 260 according to this embodiment has the same effects as those of the first embodiment.

<Third embodiment>
Hereinafter, a third embodiment of the present invention will be described. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

<Description of structure>
FIG. 13 is a partially cutaway view of the pharmaceutical composition container 400 according to this embodiment. Similar to the second embodiment, the pharmaceutical composition container 400 according to the present embodiment was obtained by folding a sheet of synthetic resin into two and bonding the ends of the folded sheet to each other. It is formed by cutting out the part and adjusting the outer shape.

  A portion where the ends of the sheet are bonded together is an outer peripheral strong seal portion 410. A plurality of spaces are provided inside the pharmaceutical composition container 400. The plurality of spaces are closed by the first weak seal portion 440, the second weak seal portion 442, and the third weak seal portion 444. The first weak seal portion 440 includes a first weak seal band 450, an intermediate chamber 452, and a second weak seal band 454.

  One of those spaces is a swallowing auxiliary substance storage chamber 420. The swallowing auxiliary substance 40 is accommodated in the swallowing auxiliary substance accommodation chamber 420. When a force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 400, the first weak seal band 450 and the second weak seal band 454 are the first weak seal portion 300 and the second weak seal portion of the second embodiment. The seal portion 302 and the third weak seal portion 304 are sequentially opened in the same manner. The reason for such opening is the same as in the second embodiment.

  One type of space inside the pharmaceutical composition container 400 includes a first storage container chamber 422 and a second storage container chamber 424. Each of these contains a container 212. The type of the pharmaceutical composition stored in the stored product 212 stored in the first stored product storage chamber 422 is different from that stored in the stored product 212 stored in the second stored product stored chamber 424.

  There is also an open chamber 426 in one of those spaces. The opening chamber 426 serves as a chute for taking the stored item 212, like the opening chamber 286 of the second embodiment.

  Of the both ends of the pharmaceutical composition container 400, one end on the side opposite to the side where the opening chamber 426 is provided is a cover 428. The boundary between the swallowing assistance substance accommodation chamber 420 and the cover 478 is a bottom strong seal portion 412. Since the strength of the bottom strong seal portion 412 is the same as that of the outer peripheral strong seal portion 410, even if a force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 400, it does not peel off.

<Features unique to this embodiment>
Compared with the pharmaceutical composition container according to another embodiment, the unique characteristic of the pharmaceutical composition container 400 according to this embodiment is that a cover 478 is provided at one end, and the bottom strong seal portion 412 and the opening chamber 426 are provided. The base of the provided portion is bent, the portion provided with the opening chamber 426 is inserted into the cover 478, the tip 480 of the portion provided with the opening chamber 426 is rounded, and the cover A portion of the edge 482 of 478 is cut away. In the description of the pharmaceutical composition container 400 according to the present embodiment, a portion closer to the second storage container chamber 424 than the cover 478 is referred to as a “container body”.

<Usage>
When using the pharmaceutical composition container 350 according to the present embodiment, one of the both ends of the pharmaceutical composition container 400 in which the opening chamber 426 is provided is pulled out from the cover 478. Subsequent usage is the same as in the other embodiments.

<Description of effects>
During production, the pharmaceutical composition container 400 according to the present embodiment is bent so that the portion where the opening chamber 426 is provided and the notched edge 482 of the cover 478 face each other. FIG. 14 shows the situation where the pharmaceutical composition container 400 is folded during manufacture. After the pharmaceutical composition container 400 is folded, the portion provided with the opening chamber 426 is inserted into the cover 478. At this time, the tip 480 of the portion where the opening chamber 426 is provided is caught at any part of the notched edge 482 of the cover 478 to open the mouth of the cover 478. Since the mouth of the cover 478 is opened, the tip 480 enters the cover 478 smoothly. FIG. 15 shows the pharmaceutical composition container 400 after the portion provided with the opening chamber 426 has been inserted into the cover 478.

  Moreover, the pharmaceutical composition container 400 according to the present embodiment has the same effects as those of the first embodiment.

<Fourth embodiment>
The fourth embodiment of the present invention will be described below. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

<Description of structure>
FIG. 16 is a partially cutaway view of a pharmaceutical composition container 500 according to this embodiment. Similar to the second embodiment, the pharmaceutical composition container 500 according to the present embodiment was obtained by folding a sheet of synthetic resin into two and bonding the ends of the folded sheet to each other. It is formed by cutting out the part and adjusting the outer shape.

  A portion where the ends of the sheet are bonded together is an outer peripheral strong seal portion 510. A plurality of spaces are provided inside the pharmaceutical composition container 500. The plurality of spaces are closed with a first weak seal portion 540, a second weak seal portion 542, and a third weak seal portion 544. The first weak seal portion 540 includes a first weak seal band 550, an intermediate chamber 552, and a second weak seal band 554.

  One of the spaces inside the pharmaceutical composition container 500 is a swallowing auxiliary substance storage chamber 520. A swallowing assistance substance 40 is housed in the swallowing assistance substance accommodation chamber 520. When force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 500, the first weak seal band 550 and the second weak seal band 554 are the first weak seal part 300 and the second weak seal part of the second embodiment. The seal portion 302 and the third weak seal portion 304 are sequentially opened in the same manner. The reason for such opening is the same as in the second embodiment.

  One type of space inside the pharmaceutical composition container 500 includes a first storage container chamber 522 and a second storage container chamber 524. Each of these contains a container 212. The type of the pharmaceutical composition stored in the stored product 212 stored in the first stored product storage chamber 522 is different from the type of the pharmaceutical composition stored in the stored product 212 stored in the second stored product stored chamber 524.

  There is also an open chamber 526 in one of those spaces. The opening chamber 526 serves as a chute for taking the inclusion 212, like the opening chamber 286 of the second embodiment.

  Of the both ends of the pharmaceutical composition container 500, one end on the opposite side to the side where the opening chamber 526 is provided is a cover 528. A boundary between the swallowing auxiliary substance storage chamber 520 and the cover 528 is a bottom strong seal portion 512. Since the strength of the bottom strong seal portion 512 is the same as that of the outer peripheral strong seal portion 510, even if a force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 500, it does not peel off. In the description of the pharmaceutical composition container 500 according to the present embodiment, a portion closer to the second storage container chamber 524 than the cover 528 is referred to as a “container body”.

<Features unique to this embodiment>
FIG. 17 is a partially cutaway view showing one end of the pharmaceutical composition container 500 being manufactured. FIG. 18 is a perspective view showing one end of the pharmaceutical composition container 500 being manufactured. With reference to FIG. 17 and FIG. 18, the unique features of the pharmaceutical composition container 500 according to this embodiment when compared with the pharmaceutical composition container according to another embodiment will be described. The feature is that the bottom strong seal portion 512 and the base of the portion where the opening chamber 526 is provided are bent, the portion where the opening chamber 526 is provided is inserted into the cover 528, and the outer peripheral strong seal portion 510 is That is, a welding margin 514 is provided at the tip portion 516 inserted into the cover 528. The welding margin 514 is folded back as shown in FIG. 18 and welded to the tip portion 516.

<Usage>
The method of using the pharmaceutical composition container 500 according to this embodiment is the same as that of the third embodiment.

<Description of effects>
Since the pharmaceutical composition container 500 according to the present embodiment has the above-described structure, even if a burr is generated at the end of the outer peripheral strong seal portion 510, the burr is difficult to contact the patient's mouth. Because burr is difficult to touch, it is hard to hurt patient's mouth.

  Moreover, the pharmaceutical composition container 500 according to the present embodiment has the same effects as those of the first embodiment.

<Fifth embodiment>
The fifth embodiment of the present invention will be described below. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

<Description of structure>
FIG. 19 is a partially cutaway view of the pharmaceutical composition container 210 according to this embodiment. Similar to the second embodiment, the pharmaceutical composition container 210 according to the present embodiment was obtained by folding a sheet of synthetic resin into two and bonding the ends of the folded sheet to each other. It is formed by cutting out the part and adjusting the outer shape.

  The portions where the ends of the sheet are bonded together are the outer peripheral strong seal portions 220 and 222. A plurality of spaces are provided inside the pharmaceutical composition container 210. A space between the plurality of spaces is closed with a first weak seal portion 240, a second weak seal portion 242, and a third weak seal portion 244. The first weak seal portion 240 has a first weak seal band 250, an intermediate chamber 252, and a second weak seal band 254.

  One of the spaces inside the pharmaceutical composition container 210 is a swallowing auxiliary substance storage chamber 230. The swallowing assistance substance 40 is housed in the swallowing assistance substance storage chamber 230. When a force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 260, the first weak seal band 250 and the second weak seal band 254 are the first weak seal portion 300 and the second weak seal portion of the second embodiment. The seal portion 302 and the third weak seal portion 304 are sequentially opened in the same manner. The reason for such opening is the same as in the second embodiment.

  One type of space inside the pharmaceutical composition container 210 also includes a first storage container chamber 232 and a second storage container chamber 234. Each of these contains a container 212. The pharmaceutical composition stored in the storage 212 stored in the first storage container 232 is different from the pharmaceutical composition stored in the storage 212 stored in the second storage container 234. . Moreover, these stored items 212 have different external shapes from the stored items 42 of the first embodiment.

  There is also an open chamber 236 in one of the spaces inside the pharmaceutical composition container 210. The opening chamber 236 serves as a chute for taking the stored item 212, like the opening chamber 286 of the second embodiment.

  The pharmaceutical composition container 210 according to this embodiment is wound so that the opening chamber 236 is surrounded by the swallowing auxiliary substance storage chamber 230. Since the pharmaceutical composition container 210 may be straightened from the time it is completed until it is used, the wound pharmaceutical composition container 210 may have the end of the swallowing assistance substance storage chamber 230 attached to the tape 214. It is fastened with. FIG. 20 shows a rolled pharmaceutical composition container 210.

<Usage>
When using the pharmaceutical composition container 210 according to this embodiment, the tape 214 is peeled off and the pharmaceutical composition container 210 is straightened. When the pharmaceutical composition container 210 extends straight, the open chamber 236 is placed in the patient's mouth. Thereafter, the inclusion 212 is taken in the same manner as in the first embodiment and its modifications.

<Description of effects>
The pharmaceutical composition container 210 according to this embodiment has the same effects as those of the first embodiment.

  The pharmaceutical composition container according to the present invention can be suitably used as a container for taking medicine. In particular, the container for taking medicine can be suitably used for a medicine filled by the system described below. The system is a system in which a plurality of auger filling machines are installed, a transport system and a weighing system are added, connected to a pharmaceutical production line, and automatic operation is performed for a long time.

10, 11, 12, 14, 15, 16, 18, 210, 260, 400, 500 Pharmaceutical composition container 20 Sheet 22 Auxiliary substance containing bag 30, 100, 102, 104, 106, 230, 280, 520 Swallowing auxiliary substance Storage chambers 32, 110 Storage container chambers 34, 150 Exit chamber 36 First bag storage chamber 38 Second bag storage chamber 40 Swallowing assisting substances 42, 120, 212 Storage 50 Cut portion 60 Opening scheduled portions 70, 240, 300, 440, 540 First weak seal portion 72, 242, 302, 442, 542 Second weak seal portion 74, 220, 222, 270, 410, 510 Outer peripheral strong seal portion 76, 244, 304, 444, 544 Third Weak seal portion 80 Pharmaceutical composition 90 Patient 112,232,282,422,522 First containment chamber 114,234,284,4 24,524 Second storage chamber 116 Empty chamber 130 First taper portion 140 Second taper portion 214 Tape 236, 286, 426, 526 Open chamber 238, 288, 428, 478, 528 Cover 250, 310, 450, 550 First weak seal band 252, 312, 452, 552 Intermediate chamber 254, 314, 454, 554 Second weak seal band 262 Label 272, 412, 512 Bottom strong seal part 320 Cover insertion part 330 Base 480 Tip 482 Edge 516 Tip part

Claims (6)

A pharmaceutical composition container comprising a plurality of spaces,
The space between two adjacent spaces is closed,
The space between the two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container,
A swallowing aid substance is housed in a swallowing aid substance containing chamber that is at least one of the spaces;
A storage is stored in a storage room that is at least one of the spaces,
The encasement contains a pharmaceutical composition,
At least the surface of the inclusion is dissolved in the swallowing aid component;
A pharmaceutical composition container characterized in that an opening formation scheduled portion for forming an opening for communicating the outside of the pharmaceutical composition container and the space is provided. The swallowing aid contains water,
The pharmaceutical composition container according to claim 1, wherein the material of the encapsulated material is a water-soluble substance, so that at least the surface of the encapsulated material is dissolved in the component of the swallowing auxiliary substance. The swallowing aid is a jelly containing water;
The pharmaceutical composition container according to claim 2, wherein the water-soluble substance is starch.   2. The pharmaceutical composition container according to claim 1, wherein an empty chamber that is at least one of the spaces is disposed between the swallowing auxiliary substance storage chamber and the storage container storage chamber.   The pharmaceutical composition container according to claim 1, wherein the inclusion is sealed. A pharmaceutical composition container comprising at least three spaces,
The space between two adjacent spaces is closed,
The space between the two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container,
A swallowing aid substance is housed in a swallowing aid substance containing chamber that is at least one of the spaces;
A storage is stored in a storage room that is at least one of the spaces,
The encasement contains a pharmaceutical composition,
At least the surface of the inclusion is dissolved in the swallowing aid component;
An opening chamber that is at least one of the spaces is provided with an opening that allows the outside of the pharmaceutical composition container to communicate with the space.

Images